帕博利珠单抗相关发疹性角化棘皮瘤
本文报告3例接受帕博利珠单抗治疗的癌症患者出现发疹性角化棘皮瘤(KA)。皮损在用药中位13个月后于日晒部位突然多发,组织见苔藓样浸润。局部糖皮质激素±冷冻治疗使KA消退,且未中断帕博利珠单抗,原发肿瘤均完全缓解。
要点
- 帕博利珠单抗可诱发发疹性KA,多在用药中位13个月后于日晒部位出现。
- 皮损组织见苔藓样浸润,以CD3+ T细胞为主,类似抗PD-1相关苔藓样皮炎。
- 局部糖皮质激素±冷冻可使KA消退,无需停用帕博利珠单抗。
核心结论
- 帕博利珠单抗治疗可能与发疹性KA相关,伴特征性真皮炎症。
- 局部糖皮质激素单用或联合冷冻可改善KA,允许继续帕博利珠单抗治疗。
研究设计与样本
- 病例报告研究,纳入2个中心的3例接受帕博利珠单抗治疗的癌症患者。
- 3例患者均发生发疹性KA,其中2男1女,中位年龄83岁(范围77-91岁)。
主要发现
- 3例患者均在帕博利珠单抗治疗中位13个月(范围4-18个月)后,于四肢日晒部位突然出现多发皮损。
- 皮损活检显示真皮苔藓样浸润,主要由CD3+ T细胞、散在CD20+ B细胞及相对较少的PD-1+ T细胞组成。
- 所有患者的KA均消退,密切随访期间无新发皮损。
- 3例均未中断帕博利珠单抗治疗,且原发癌症均获完全缓解。
关键数值与推荐
- 3例患者均接受氯倍他索软膏和病灶内曲安奈德治疗,其中2例还接受开放性表浅冷冻手术。
临床怎么用
- 对帕博利珠单抗治疗患者出现日晒部位多发KA时,应考虑药物相关发疹性KA。
- 局部糖皮质激素和病灶内曲安奈德单用或联合冷冻手术可有效控制KA。
- KA控制后无需中断帕博利珠单抗治疗。
局限性
- 本文为3例病例报告,样本量小,不能确立因果关系或估计发生率。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: To our knowledge, there have been no previous reports of eruptive keratoacanthomas (KAs) in patients receiving pembrolizumab. OBJECTIVE: To report the cases of 3 consecutive patients with pembrolizumab-induced eruptive KAs and their management. DESIGN, SETTING, AND PARTICIPANTS: Case report study of 3 patients from 2 centers with pembrolizumab-treated cancer who all developed eruptive KAs. INTERVENTIONS: All 3 patients had AK treatment with clobetasol ointment and intralesional triamcinolone; 2 patients also underwent open superficial cryosurgery. RESULTS: Three consecutive patients with cancer, 2 men and 1 woman (median age, 83 years; range 77-91 years), experienced pembrolizumab-associated eruptive KAs. All patients presented with a sudden onset of multiple lesions on sun-exposed areas of their extremities after a median of 13 months (range, 4-18 months) of pembrolizumab therapy. On lesional biopsy, a lichenoid infiltrate was observed in the underlying dermis, predominantly composed of CD3+ T cells, scattered CD20+ B cells, and relatively few PD-1+ (programmed cell death 1-positive) T cells, an immunophenotypic pattern also observed in other cases of anti-PD-1-induced lichenoid dermatitis. Patients were treated with clobetasol ointment and intralesional triamcinolone, alone or in combination with open superficial cryosurgery. All KAs resolved in all patients, and no new lesions occurred during close follow-up. Pembrolizumab treatment was continued without disruption in all 3 cases, and all patients had complete responses of their primary cancers. CONCLUSIONS AND RELEVANCE: Pembrolizumab is used in advanced melanoma, advanced non-small-cell lung cancer, and in head and neck cancer. A variety of dermatologic immune-related adverse events including maculopapular eruption, lichenoid reactions, pruritus, and vitiligo have been described. This case series demonstrates that pembrolizumab therapy may also be associated with eruptive KAs with characteristic dermal inflammation, which improved with corticosteroid treatment (topical and intralesional) alone or in combination with cryosurgery, allowing patients to continue therapy with pembrolizumab.
引用
- Freites-Martinez A, Kwong BY, Rieger KE, et al. Eruptive Keratoacanthomas Associated With Pembrolizumab Therapy. JAMA Dermatol. 2017. PMID: 28467522. doi:10.1001/jamadermatol.2017.0989
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。